Jefferies Group LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $304,633 - $554,786	-10,962 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $434,314 - $767,011	10,962 New	10,962 $7,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $871,350 - $1.24 Million	-15,000 Closed	0 $0
Q3 2021 Sep 21, 2023	SELL	$58.38 - $84.96 $1.46 Million - $2.13 Million	-25,062 Reduced 62.56%	15,000 $936,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $1.46 Million - $2.13 Million	-25,062 Reduced 62.56%	15,000 $936,000
Q2 2021 Sep 21, 2023	SELL	$62.15 - $90.32 $1.33 Million - $1.93 Million	-21,361 Reduced 34.78%	40,062 $3.32 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $1.33 Million - $1.93 Million	-21,361 Reduced 34.78%	40,062 $3.32 Million
Q1 2021 Sep 21, 2023	BUY	$61.35 - $90.47 $3.77 Million - $5.56 Million	61,423 New	61,423 $4.07 Million
Q1 2021 May 14, 2021	BUY	$61.35 - $90.47 $3.77 Million - $5.56 Million	61,423 New	61,423 $4.07 Million
Q4 2019 Feb 13, 2020	SELL	$28.14 - $73.01 $160,116 - $415,426	-5,690 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$26.26 - $34.86 $133,216 - $176,844	5,073 Added 822.2%	5,690 $160,000
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $10,754 - $17,781	617 New	617 $16,000
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $23,628 - $43,340	-2,200 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $7,000 - $10,150	500 Added 29.41%	2,200 $42,000
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $78,351 - $172,446	-12,300 Reduced 87.86%	1,700 $23,000
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $52,080 - $106,960	14,000 New	14,000 $101,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account